Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial

NCT04672525 is registered in ClinicalTrials.gov with Tourcoing Hospital as lead sponsor.

NCT NCT04672525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial
Lead sponsor
Tourcoing Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
November 8, 2021
Completion date
June 30, 2027
Enrollment
436 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

prosthetic infection